Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 14, 2005

 

CELL THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Washington   001-12465   91-1533912

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

501 Elliott Avenue West, Suite 400

Seattle, Washington 98119

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (206) 282-7100

 

Not applicable

(Former name or former address, if changed since last report).

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 4.01. Changes in Registrant’s Certifying Accountant

 

On October 14, 2005, the audit committee of the board of directors of Cell Therapeutics, Inc. (the “Company”) engaged Stonefield Josephson, Inc. (“Stonefield Josephson”) as the Company’s new independent auditors to provide financial audit services effective immediately. The engagement will commence with the review of the Company’s financial results for the third quarter ended September 30, 2005, as well as the audit of its current fiscal year which ends December 31, 2005. Stonefield Josephson has not audited the Company’s financial statements in the two most recent fiscal years or any subsequent interim period.

 

Additionally, during the last two fiscal years and the subsequent interim period through October 14, 2005, the Company did not consult with Stonefield Josephson regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

 

-1-

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

CELL THERAPEUTICS, INC.

Date: October 14, 2005

       By:  

/s/ Louis A. Bianco

               

Louis A. Bianco

Executive Vice President, Finance and Administration (Principal Accounting Officer)

 

-2-